Abstract:One potential approach to address the rising threat of antibiotic resistance is through novel formulations of established drugs. We designed antibiotic cross-linked micelles (ABC-micelles) by cross-linking the Pluronic F127 block copolymers with an antibiotic itself, via a novel one-pot synthesis in aqueous solution. ABC-micelles enhanced antibiotic encapsulation while also reducing systemic toxicity in mice. Using colistin, a hydrophilic, potent ″last-resort" antibiotic, ABC-micelle encapsulation yield was 80%, with good storage stability. ABC-micelles exhibited an improved safety profile, with a maximum tolerated dose of over 100 mg/kg colistin in mice, at least 16 times higher than the free drug. Colistin-induced nephrotoxicity and neurotoxicity were reduced in ABC-micelles by 10–50-fold. Despite reduced toxicity, ABC-micelles preserved bactericidal activity, and the clinically relevant combination of colistin and rifampicin (co-loaded in the micelles) showed a synergistic antimicrobial effect against antibiotic-resistant strains of Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. In a mouse model of sepsis, colistin ABC-micelles showed equivalent efficacy as free colistin but with a substantially higher therapeutic index. Microscopic single-cell imaging of bacteria revealed that ABC-micelles could kill bacteria in a more rapid manner with distinct cell membrane disruption, possibly reflecting a different antimicrobial mechanism from free colistin. This work shows the potential of drug cross-linked micelles as a new class of biomaterials formed from existing antibiotics and represents a new and generalized approach for formulating amine-containing drugs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c21459?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c21459</a>.Material and reagents; Characterization of NPC-F127 and ABC-micelles, including NMR, yield, standard curves, parameters and stability; MIC and MBC data; toxicity, as well as hematoxylin and eosin-stained section and MTDs; CFUs and inflammatory biomarker of sepsis model; and microscopy imaging and movies (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21459/suppl_file/am0c21459_si_001.pdf">PDF</a>)Movie 1: Real-time imaging of bacteria treated by 16 μg/mL colistin ABC-micelles with rapid change of morphology (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21459/suppl_file/am0c21459_si_002.avi">AVI</a>)Movie 2: Real-time imaging of bacteria treated by colistin with no significant morphology change (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21459/suppl_file/am0c21459_si_003.avi">AVI</a>)Movie 3: Real-time imaging of bacteria treated by 32 μg/mL colistin ABC-micelles with rapid change of morphology (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21459/suppl_file/am0c21459_si_004.avi">AVI</a>)This article has not yet been cited by other publications.

Metabolic Engineering of "Last-line Antibiotic" Colistin in Paenibacillus polymyxa

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Crafting Stable Antibiotic Nanoparticles via Complex Coacervation of Colistin with Block Copolymers

Polymyxins with Potent Antibacterial Activity against Colistin-Resistant Pathogens: Fine-Tuning Hydrophobicity with Unnatural Amino Acids

Combining Colistin with Furanone C-30 Rescues Colistin Resistance of Gram-Negative Bacteria in Vitro and in Vivo

Design, Synthesis and Antibacterial Activity of Novel Colistin Derivatives with Thioether Bond-Mediated Cyclic Scaffold.

Combinatorial metabolic engineering of Bacillus subtilis for de novo production of polymyxin B

Paenimacrolidin, a Novel Macrolide Antibiotic from Paenibacillus Sp. F6‐B70 Active Against Methicillin‐resistant Staphylococcus Aureus

Pharmacokinetics and Pharmacodynamics of 'old' Polymyxins: What is New?

Intravenous Colistimethate for Multidrug-Resistant Gram-negative Bacteria.

Restoring Colistin Sensitivity and Combating Biofilm Formation: Synergistic Effects of Colistin and Usnic Acid against Colistin-Resistant Enterobacteriaceae

The synergistic antibacterial activity and mechanism of colistin-oxethazaine combination against gram-negative pathogens

Morphological, genomic and transcriptomic responses of Klebsiella pneumoniae to the last-line antibiotic colistin

Synthesis, Characterization, and Biological Evaluation of Chitosan Nanoparticles Cross-Linked with Phytic Acid and Loaded with Colistin against Extensively Drug-Resistant Bacteria

Restoring colistin sensitivity in colistin-resistant Salmonella and Escherichia coli: combinatorial use of berberine and EDTA with colistin

Clinical Pharmacokinetics and Pharmacodynamics of Colistin

PK/PD of Polymyxins Against Gram-Negative ?Superbugs?

Repurposing cetylpyridinium chloride and domiphen bromide as phosphoethanolamine transferase inhibitor to combat colistin-resistant Enterobacterales

Antibiotic Cross-linked Micelles with Reduced Toxicity for Multidrug-Resistant Bacterial Sepsis Treatment

An Evolutionarily Conserved Mechanism for Intrinsic and Transferable Polymyxin Resistance.